Bile Acid Sequestrants
Introduction to Bile Acid Sequestrants
- Bile acid sequestrants are non-absorbable resins that bind to bile acids in the intestine, forming insoluble complexes that are excreted in the feces, preventing their reabsorption in the enterohepatic cycle, as noted by the American Gastroenterological Association 1
Types of Bile Acid Sequestrants
- Cholestyramine is an anion exchange resin powder, considered first-line treatment for bile acid diarrhea, although it is often poorly tolerated due to its unpleasant taste and side effects, according to the European Society of Gastrointestinal Endoscopy 1, 2
- Colesevelam is a second-generation sequestrant available in tablets, with a different structure that maximizes interaction with bile salts and reduces the potential for interactions with other medications, generally better tolerated than cholestyramine, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 3
Clinical Indications
- Bile acid diarrhea (BAD) is a common but often underdiagnosed condition that responds well to sequestrant treatment, as stated by the American College of Gastroenterology 1, 4, 5
- Diarrhea induced by oncologic treatment: sequestrants can be used as adjuvant therapy in cases of diarrhea associated with bile acid malabsorption after chemotherapy or radiation therapy, according to the European Society for Medical Oncology 3, 6
Administration and Dosage
- Colesevelam can be started with two tablets twice a day and titrated according to effect, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 3
- Sequestrants should be administered with meals, not on an empty stomach, to improve tolerance, as suggested by the American Gastroenterological Association 3
Important Considerations and Precautions
- Drug interactions: sequestrants can bind to other medications administered concomitantly, requiring separation in administration, as noted by the American College of Clinical Pharmacy 1
- Recommendation: other medications should be taken at least 1 hour before or 4-6 hours after sequestrants, as recommended by the American College of Clinical Pharmacy 1
- Deficiency of fat-soluble vitamins: prolonged use can interfere with the absorption of vitamins A, D, E, and K, potentially requiring supplementation if deficiency occurs, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 1
Efficacy
- In patients with bile acid diarrhea diagnosed by SeHCAT, colesevelam demonstrated superiority over placebo in inducing remission, as stated by the European Society of Gastrointestinal Endoscopy 2, 7
- The response to sequestrant treatment correlates with the severity of bile acid malabsorption, according to the National Institute of Diabetes and Digestive and Kidney Diseases 2, 7
Special Considerations
- In patients who do not respond to cholestyramine, colesevelam can be an effective alternative, as suggested by the American College of Gastroenterology 2, 7
- Vitamin D deficiency occurs in 20% of patients using bile acid sequestrants, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 3
- After discontinuation of sequestrant treatment, approximately 41.6% of patients experience recurrence of symptoms, according to the European Society for Medical Oncology 4, 8
Bile Acid Sequestrants in Diarrhea Management
Mechanism and Contraindications
- Bile acid sequestrants can worsen diarrhea and steatorrhea in patients without bile acid malabsorption, particularly in those with severe bile acid loss or short bowel syndrome, and should generally be avoided in these contexts 9
- In patients with extensive ileal disease or resection (>100 cm), the bile acid pool is already severely depleted, and adding sequestrants further reduces available bile acids needed for fat digestion, exacerbating steatorrhea and fat-soluble vitamin deficiencies 9
- The American Gastroenterological Association (AGA) explicitly recommends avoiding bile acid sequestrants in short bowel syndrome unless there is clear evidence of bile acid malabsorption 9
- Sequestrants may worsen fat-soluble vitamin losses that are already problematic in patients with short bowel syndrome 9
- Alternative antidiarrheal agents (loperamide, codeine, tincture of opium) should be used instead of sequestrants in patients with short bowel syndrome or severe bile acid malabsorption 9
Clinical Context and Guidelines
- The AGA recommends confirming the presence of bile acid malabsorption through SeHCAT testing, serum C4, or clinical risk factors before prescribing bile acid sequestrants 10
- The Canadian Association of Gastroenterology suggests diagnostic testing over empiric sequestrant therapy when available 10
- An empiric trial of bile acid sequestrants is reasonable only when bile acid diarrhea is clinically suspected, testing is unavailable, and there is no evidence of severe malabsorption or short bowel syndrome 10
Diagnostic Approach for Bile Acid Diarrhea
Introduction to Bile Acid Diarrhea Diagnosis
- The British Society of Gastroenterology recommends obtaining objective testing with SeHCAT or serum C4 before initiating bile acid sequestrant therapy for patients with suspected bile acid diarrhea, as 44% of patients with confirmed bile acid diarrhea fail to respond to cholestyramine alone 11, 12
- Lack of response to cholestyramine does not exclude bile acid diarrhea as the underlying diagnosis, highlighting the need for objective testing 11, 12
- The response rate to bile acid sequestrants correlates with severity, with 96% responding with <5% SeHCAT retention, 80% with <10% retention, and 70% with <15% retention 11, 12
Diagnostic Testing
- SeHCAT testing or serum C4 levels should be performed before starting treatment to confirm the diagnosis of bile acid diarrhea 11, 12
- A systematic review of 5,028 patients found that 25% previously diagnosed with functional diarrhea actually had primary bile acid diarrhea when properly tested with SeHCAT or serum C4 11, 12
Treatment Approach
- If therapeutic trials are considered, switching to colesevelam rather than abandoning bile acid sequestrant therapy entirely is recommended if cholestyramine appears ineffective after 4-8 weeks 11, 12